论文部分内容阅读
目的探讨HBeAg阳性慢性乙型肝炎患者采用苦参素片联合恩替卡治疗的临床效果。方法回顾性分析2014年1月至2015年6月106例HBeAg阳性慢性乙型肝炎患者的临床资料,按照治疗方案分为单药组和联合组,每组53例,单药组给予恩替卡韦治疗,联合组采用苦参素片联合恩替卡韦治疗。比较两组患者治疗前后的血清学指标及病毒指标的变化。结果治疗后,联合组、单药组丙氨酸氨基转移酶(ALT)、HBV DNA水平较治疗前降低,差异均有统计学意义(t=20.9677、20.0658,P<0.05);但同组治疗前后ALT、HBV DNA水平比较差异均未见统计学意义(P>0.05)。治疗后,联合组HBeAg转阴率、HBeAg转换率、HBV DNA阴转率均优于单药组(39.62%比20.75%,32.08%比15.09%,92.45%比77.36%),差异均有统计学意义(P<0.05)。结论苦参素和恩替卡韦联合治疗Be Ag阳性慢性乙型肝炎可提高机体抗病毒效果,增高机体免疫能力,不良反应少,有助于提高患者生活质量。
Objective To investigate the clinical effect of oxymatrine combined with oxymatrine on HBeAg-positive chronic hepatitis B patients. Methods The clinical data of 106 patients with HBeAg-positive chronic hepatitis B from January 2014 to June 2015 were retrospectively analyzed. According to the treatment regimen, they were divided into single drug group and combined group, with 53 patients in each group. Entecavir was used in the single drug group, The combination group used oxymatrine tablets combined with entecavir treatment. Serum and viral indices before and after treatment were compared between the two groups. Results After treatment, the levels of alanine aminotransferase (ALT) and HBV DNA in the combination group and the single drug group were significantly lower than those before treatment (t = 20.9677, 20.0658, P <0.05) Before and after ALT, HBV DNA levels were no significant difference (P> 0.05). After treatment, the HBeAg negative rate, HBeAg conversion rate and HBV DNA negative rate in the combined group were better than those in the single drug group (39.62% vs. 20.75%, 32.08% vs 15.09%, 92.45% vs 77.36%), with statistical differences Significance (P <0.05). Conclusion Oxymatrine and entecavir combined with Be Ag-positive chronic hepatitis B can enhance the antiviral effect of the body and increase the immunity of the body with less adverse reactions, which can help improve the quality of life of patients.